A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Neoplasms
Lung Neoplasms
Urinary Bladder Neoplasms
Breast Neoplasms

Interventions

DRUG: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)

Sponsor

National Cancer Institute (NCI)